NEW YORK (GenomeWeb News) – Clinical Data has signed an agreement with the Blue Cross and Blue Shield Association to offer its genetic tests for inherited cardiac syndromes to BCBSA member companies.
The agreement will give BCBSA's 39 member companies access to the Familion Long QT Syndrome test, which is offered through Clinical Data's PGxHealth division. The individual insurers will be able to independently enter into an ancillary contract to offer the tests to their members.
The Familion group of tests detect mutations that can cause cardiac channelopathies or cardiomyopathies, such as Long QT Syndrome; Brugada Syndrome; Catecholaminergic Polymorphic Ventricular Tachycardia; Hypertrophic Cardiomyopathy; and Arrhythmogenic Right Ventricular Cardiomyopathy
Clinical Data said that nearly 200 million patients in the US are now covered by providers and private payers who offer access to the firm's genetic tests.